Our first CarboHyde India seminar in Baddi was a lifetime experience and memory for me.
The hospitality and kindness of the local pharma experts was heartwarming.
Heartful thanks to DR NASEEM KHAN, Dr S K Chauhan and Raman Singh along with our local team for the excellent planning and organization.
I see a bright future for our sister company with such devoted and passionate team.
I am deeply honored to be invited by PhD Circle (Gjylije Hoti & Visar Vela) to talk about The CarboHyde story
My title is “From Vision to Impact: The Cyclodextrin Revolution at CarboHyde.”
Join us online to discover how innovative applications of cyclodextrins are driving breakthroughs across industries, and how scientific vision can be transformed into real-world impact through entrepreneurship and cutting-edge research.
🗓️ 21 May, 2026
🕖 19:00 CET
📍 Online
🔗https://lnkd.in/da-zSjXH
Don’t miss this opportunity to be a part of the conversation shaping tomorrow’s innovations.
Our Indian branch is diving deep into the uses of silicon dioxide and DR NASEEM KHAN will share a lot about its pharma uses and possibilities.
What if one of the most widely used materials in drug formulation is also one of the most promising for the future?
Join us for an insightful webinar exploring the evolving role of silicon dioxide in the pharmaceutical industry. From enhancing drug stability to improving delivery systems, this versatile excipient is shaping the next generation of medicines.
What you’ll learn:
– The functional benefits of silicon dioxide in modern formulations
– Innovations driving its expanded use in pharmaceuticals
– Regulatory considerations and quality standards
– Future trends and research breakthroughs
Silicon Dioxide in Pharmaceuticals – A Future Excipient – CarboHyde
CanGoNano is a Marie Skłodowska-Curie Doctoral Network (MSCA-DN) bringing together universities, research institutes, and industry partners across Europe to explore a fast-emerging field: glyconanomaterials (GNMs).
The mission is straightforward but ambitious—design nanoscale systems built from carbohydrates that can interact with the immune system in highly specific ways. These systems could reshape how we approach cancer immunotherapy, vaccines, and targeted drug delivery.
Rather than focusing on a single discipline, CanGoNano sits at the crossroads of:
This interdisciplinary approach is also reflected in the structure of the programme: multiple doctoral candidates (DCs) working on complementary projects across Europe, each contributing a piece to the bigger picture.
Glyconanomaterials are nanostructures that incorporate carbohydrates (sugars) to mimic or influence biological processes. Because sugars play a key role in how cells communicate—especially in immune recognition—they are powerful tools for designing smarter therapeutics.
Applications being explored in CanGoNano include:
The CanGoNano network offers multiple PhD positions (Doctoral Candidates, DCs) hosted by leading institutions and companies. Each position focuses on a specific scientific angle while contributing to the shared goal of advancing glyconanomaterials.
Here is a high-level overview of the positions and their locations:
Among the positions, DC-4 in Budapest highlights an important class of carbohydrate-based materials: cyclodextrins.
Hosted by CarboHyde, this project explores how cyclodextrins—ring-shaped sugar molecules—can be engineered into nanocarriers.
Their unique structure allows them to:
In the context of CanGoNano, they are being developed into delivery platforms for biologics, including nucleic acids and immune-active compounds.
A defining feature of CanGoNano is its training philosophy. Doctoral candidates are not only conducting research—they are part of a structured programme that includes:
This ensures graduates are prepared for careers in biotech, pharma, and advanced materials research.
CanGoNano reflects a broader shift in science: moving from isolated discoveries toward integrated, application-driven research ecosystems.
By combining:
the project aims to unlock new strategies for treating complex diseases.
And just as importantly, it is building a cohort of researchers equipped to carry those innovations forward.
In this patent (WO 2026/018002 A1) from Genomic Labs the inventors describe obtaining DNA of a bacterial or fungal pathogen from a mammalian blood sample via a series of purification steps.
During the purification process, cyclodextrins are also used to improve the efficiency of microbial lysis and nucleic acid extraction in addition to it providing microbial nucleic acid amplification efficiency.
WO2026018002 METHOD OF PURIFYING BACTERIAL OR FUNGAL PATHOGEN DNA FROM BLOOD SAMPLE
Retinol is one of the most powerful actives in skincare—but also one of the most challenging to formulate.
In this short deck, we explore how cyclodextrin complexation can unlock better retinol performance by addressing its biggest formulation hurdles:
• Improved chemical stability against oxidation, UV, and heat
• Reduced irritation risk through controlled, gradual release
• Maintained bioavailability via reversible complexation
• Simpler formulation systems compared with traditional encapsulation approaches
The result: better tolerability, sustained activity, and improved commercial viability for retinol-based products.
Curious how it works in practice?
Take a look at the full deck 👇
Sounds exciting and dangerously misleading.
What generative AI can realistically do in scientific research is find relevant papers when connected to real databases, accelerate structured summaries and cross-paper comparisons, and polish rough drafts into precise, evidence-based language. What it cannot do is guarantee that a single citation it generates actually exists.
At the 2nd Bicyclos HEurope International School and Workshop in Sevilla, our very own Milo Malanga PhD delivered a hands-on session on the responsible use of generative AI in literature search, analysis and proposal writing, putting five major AI platforms to the test with a deliberately fabricated citation request. Some tools generated complete references to authors, journals, and DOIs to a paper that was never written, while others searched real databases and returned only verified sources.
The difference between a hallucinated DOI in your MSCA proposal and a verified one is not a minor detail; it is a credibility risk that can undermine months of work.
AI is a powerful accelerator for research workflows, but verification is not optional, IP protection is not an afterthought, and critical thinking is not something we can afford to outsource.
Speed matters, but accuracy matters more.
Have you ever caught an AI-generated citation that turned out to be completely fabricated? We’d love to hear how you’re navigating AI in your research workflow.
From 2026, at CarboHyde we decided to expand beyond cyclodextrin-based drug-development.
This short 2-pager captures the support we can provide locally in Hungary:
1. Drug substance development and manufacturing
2. Drug product development
3. Analytical support and CMC
4. Bioanalytical testing and toxicology
5. GMP production
6. Regulatory support
– custom synthesis
– formulation development
– analysis (of cyclodextrins and their complexes).
Learn more from Dani’s creation and get in touch if you have a problem to chat about in this field.
Ep50: Speaking Up in Science with Tamas Sohajda | Podcasts
Recently I had the chance to sit down with Louise Jefferies on her podcast Speaking up in English at Work for Introverts
– and it turned into one of the most honest conversations I’ve had about science, communication, and the fears many of us quietly carry.
My main message was simple:
Scientists are doing extraordinary work behind the scenes… but far too much of it never reaches the people who need it.
In the episode, we talked about something I see every day in our field:
most scientists stay silent — not because they lack expertise, but because they doubt whether their voice matters. And that silence costs the industry more than we realise.
We unpacked a lot, including
• why publishing papers is no longer enough
• how misinformation fills the void when experts hold back
• the visibility challenges introverts and multilingual scientists face
• the fear of posting, presenting, or speaking up (and why our imagined catastrophes almost never happen)
• why LinkedIn is actually one of the safest, kindest spaces to start sharing
• and how having a purpose makes fear feel a lot smaller
If there’s one thing I hope listeners take away, it’s this:
Your work can influence decisions, shape policy, and move our field forward — but only if your voice is heard.
You don’t need to be louder.
You don’t need to perform.
You just need to stop hiding expertise that genuinely matters.
If you’ve ever hesitated to post, present, or speak up in a meeting, this conversation might be exactly what you need.